IP Library Patent Application 11162698
Patent Application
App. No. 11/162,698

METHOD AND APPARATUS FOR PURIFYING PHARMACEUTICAL COMPOSITIONS USING SUPERCRITICAL FLUIDS

Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US None
App. No.
11/162,698
Abstract

The present invention provides a method and an apparatus for removing impurities from biodegradable polymers and/or pharmaceutical compounds. In accordance with the method, a stream of supercritical fluid and, optionally, a modifying co-solvent, is used to dissolve the impurities. The pressure and temperature of the supercritical fluid or supercritical fluid/co-solvent mixture is controlled such that the supercritical fluid or mixture acts as a solvent for the impurities, but not for the biodegradable polymers and/or pharmaceutical compounds.

Claims (39)

1 . A method of purifying a pharmaceutical composition comprising:

providing a pharmaceutical composition that comprises a biologically active substance and at least a first impurity;

loading the pharmaceutical composition into an extraction chamber;

flowing a supercritical fluid through the extraction chamber in contact the pharmaceutical composition at a first temperature and at a first pressure in which the first impurity is soluble in the supercritical fluid but the biologically active substance is not;

monitoring the concentration of the first impurity dissolved in the supercritical fluid in an exit stream flowing from the extraction chamber;

stopping the flow of supercritical fluid through the extraction chamber when the concentration of the dissolved first impurity in the exit stream is at or below a predetermined level; and

depressurizing the extraction chamber to collect a purified pharmaceutical composition.

2 . The method according to claim 1 wherein the pharmaceutical composition further comprises a biodegradable polymer.

3 . The method according to claim 1 wherein the supercritical fluid is supercritical carbon dioxide.

4 . The method according to claim 1 wherein the pharmaceutical composition further comprises a second impurity and wherein after the first impurity is extracted from the pharmaceutical composition, supercritical fluid is flowed through the extraction chamber in contact the pharmaceutical composition at a second temperature and at a second pressure in which the second impurity is soluble in the supercritical fluid but the biologically active substance is not.

5 . The method according to claim 1 wherein the pharmaceutical composition is in the form of discrete particles.

6 . The method according to claim 1 wherein the pharmaceutical composition is supported by a tray inside the extraction chamber.

7 . The method according to claim 1 wherein the first impurity is selected from the group consisting of residual monomers, unreacted reagents and residual organic solvents.

8 . The method according to claim 1 wherein the concentration of the first impurity in the exit stream is monitored using a photo diode array detector.

9 . A purified pharmaceutical composition formed in accordance with the method of claim 1 .

10 . The method according to claim 1 wherein the supercritical fluid flowing through the extraction chamber in contact the pharmaceutical composition is mixed with one or more modifying co-solvents that are at least partially miscible with the supercritical fluid.

11 . The method according to claim 10 wherein the pharmaceutical composition further comprises a biodegradable polymer.

12 . The method according to claim 10 wherein the supercritical fluid is supercritical carbon dioxide.

13 . The method according to claim 10 wherein the pharmaceutical composition further comprises a second impurity and wherein after the first impurity is extracted from the pharmaceutical composition, supercritical fluid is flowed through the extraction chamber in contact the pharmaceutical composition at a second temperature and at a second pressure in which the second impurity is soluble in the supercritical fluid but the biologically active substance is not.

14 . The method according to claim 10 wherein the pharmaceutical composition is in the form of discrete particles.

15 . The method according to claim 10 wherein the pharmaceutical composition is supported by a tray inside the extraction chamber.

16 . The method according to claim 10 wherein the first impurity is selected from the group consisting of residual monomers, unreacted reagents and residual organic solvents.

17 . The method according to claim 10 wherein the concentration of the first impurity in the exit stream is monitored using a photo diode array detector.

18 . A purified pharmaceutical composition formed in accordance with the method of claim 10 .

19 . An apparatus for purifying a pharmaceutical composition comprising:

an extraction chamber for receiving a pharmaceutical composition comprising a biologically active substance and at least a first impurity;

a source of supercritical fluid connected to the extraction chamber for flowing supercritical fluid into the extraction chamber;

a valve for adjusting the pressure within the extraction chamber;

a heating jacket disposed on the extraction chamber for adjusting the temperature within the extraction chamber;

a plurality of trays disposed within the extraction chamber for supporting the pharmaceutical composition; and

a photo diode array detector connected to an exit flow from the extraction chamber for monitoring the concentration of the first impurity dissolved in the supercritical fluid.

20 . An apparatus for purifying a pharmaceutical composition comprising:

an extraction chamber for receiving a pharmaceutical composition comprising a biologically active substance and at least a first impurity;

a source of supercritical fluid connected to the extraction chamber for flowing supercritical fluid into the extraction chamber;

a source of at least one co-solvent connected to the extraction chamber for mixing with the supercritical fluid and modifying the solvating power of the supercritical fluid;

a valve for adjusting the pressure within the extraction chamber;

a heating jacket disposed on the extraction chamber for adjusting the temperature within the extraction chamber;

a plurality of trays disposed within the extraction chamber for supporting the pharmaceutical composition; and

a photo diode array detector connected to an exit flow from the extraction chamber for monitoring the concentration of the first impurity dissolved in the supercritical fluid/co-solvent mixture.

Assignments (5)
ATTESTATION & CONFIRMATION OF SECURITY INTEREST Recorded Aug 6, 2010
From: FERRO CORPORATION
To: PNC BANK, NATIONAL ASSOCIATION (AS SUCCESSOR-BY-MERGER TO NATIONAL CITY BANK), AS COLLATERAL AGENT
Reel/Frame 024804/0117 →
RELEASE OF SECURITY INTEREST Recorded Sep 29, 2008
From: THE BANK OF NEW YORK MELLON TRUST COMPANY, N.A. (AS SUCCESSOR-IN-INTEREST TO J.P. MORGAN TRUST COMPANY)
To: FERRO CORPORATION
Reel/Frame 021590/0591 →
SECURITY AGREEMENT Recorded Jun 15, 2006
From: FERRO PFANSTIEHL LABORATORIES, INC.
To: J.P. MORGAN TRUST COMPANY, NATIONAL ASSOCIATION, AS TRUSTEE
Reel/Frame 017794/0402 →
SECURITY AGREEMENT Recorded Jun 8, 2006
From: FERRO PFANSTIEHL LABORATORIES, INC.
To: NATIONAL CITY BANK, AS COLLATERAL AGENT
Reel/Frame 017746/0052 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Nov 7, 2005
From: CHATTOPADHYAY, PRATIBHASH; SHEKUNOV, BORIS Y.
To: FERRO CORPORATION
Reel/Frame 017179/0092 →